Anika Therapeutics, Inc. (ANIK)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-09
$20.88-0.76%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Anika aims for 5% to 10% profit margin in 2026. Revenue should reach about $62.75 million. The company targets 1% to 9% revenue growth in 2026. Management is stable despite recent changes.
Anika is still losing money and faces leadership changes. Revenue growth is slow and profit margins are weak. The company missed earnings recently.
The market expects about 6% revenue growth. Our fair value is near $52, showing the stock is fairly priced for moderate growth.
Breaks if: Adjusted EBITDA margin falls below 5% in FY26
Focus on achieving an Adjusted EBITDA margin between 5% and 10% for fiscal year 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown strong revenue growth and margin expansion, indicating potential for future profitability.
The market appears to have priced in a premium valuation compared to peers, reflecting a durable premium. However, this premium may not be fully justified given the company's current loss-making status and the elevated risks involved.
Management is on track with priorities to drive revenue growth and expand margins. Recent financial performance has been strong, but there is still uncertainty around regulatory approvals for key products.
The thesis hinges on the company's ability to maintain momentum in revenue growth and margin expansion, as well as the outcomes of regulatory processes. Additionally, broader sector performance and economic indicators will play a significant role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive revenue growth trajectory. Highlights from the earnings call indicate strong revenue performance, reinforcing growth objectives. There are no new threats identified that would weaken this outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS falls below $0.41 in FY26
Breaks if: OEM Channel revenue falls below $61M in FY26
Breaks if: Revenue growth falls below 1% in FY26
Over the next 1 to 3 years, ANIK's performance will depend on its execution of growth strategies and external economic factors. Not investment advice.